Background. MicroRNAs (miRNAs) play a critical role in the carcinogenesis and progression of breast cancer. MiRNA-205 has tumor suppressive properties, whereas miRNA-18a has both oncogenic and tumor suppressive roles. MiRNA-744's role in breast cancer is unknown but is tumor-suppressive in vitro. We hypothesize that high expression of all three miRNAs is associated with a better survival based on their known functions in breast cancer. Methods. All data was obtained from the Cancer Genome Atlas (TCGA). Expression patterns of miRNA-18a, miRNA-205, and miRNA-744 were retrieved from the Genomic Data Commons (GDC) data portal for analyses. After miRNA-specific thresholds were derived and used to group the patients into a high-or low-expression group, survival data was calculated by using the Cox proportional hazard model. Further subanalyses separating the patients based on receptor status and AJCC 7th edition TNM staging were similarly compared. Results. In total, 1,052 of 1,097 samples logged in TCGA had clinical data and miRNA-sequence datasets on the miRNAs of interest. High expression of miRNA-18a (p = 0.079), miRNA-205 (p = 0.034), and miRNA-744 (p = 0.0135) was associated with better survival. On subanalysis, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and lymph node-negative disease had a statistically significant survival advantage with miRNA-18a, miRNA-205, and miRNA-744 high expression. Conclusions. By utilizing a big dataset (TCGA) with sufficient statistical power, we found that high expression of miRNA-18a, miRNA-205, and miRNA-744 in the breast tumor samples were all associated with better overall survival in ER/PR-positive, lymph node-negative disease supporting their role as a tumor suppressor in breast cancer.
ABSTRACT
Background. MicroRNAs (miRNAs) play a critical role in the carcinogenesis and progression of breast cancer. MiRNA-205 has tumor suppressive properties, whereas miRNA-18a has both oncogenic and tumor suppressive roles. MiRNA-744's role in breast cancer is unknown but is tumor-suppressive in vitro. We hypothesize that high expression of all three miRNAs is associated with a better survival based on their known functions in breast cancer. Methods. All data was obtained from the Cancer Genome Atlas (TCGA). Expression patterns of miRNA-18a, miRNA-205, and miRNA-744 were retrieved from the Genomic Data Commons (GDC) data portal for analyses. After miRNA-specific thresholds were derived and used to group the patients into a high-or low-expression group, survival data was calculated by using the Cox proportional hazard model. Further subanalyses separating the patients based on receptor status and AJCC 7th edition TNM staging were similarly compared. Results. In total, 1,052 of 1,097 samples logged in TCGA had clinical data and miRNA-sequence datasets on the miRNAs of interest. High expression of miRNA-18a (p = 0.079), miRNA-205 (p = 0.034), and miRNA-744 (p = 0.0135) was associated with better survival. On subanalysis, estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and lymph node-negative disease had a statistically significant survival advantage with miRNA-18a, miRNA-205, and miRNA-744 high expression.
Conclusions. By utilizing a big dataset (TCGA) with sufficient statistical power, we found that high expression of miRNA-18a, miRNA-205, and miRNA-744 in the breast tumor samples were all associated with better overall survival in ER/PR-positive, lymph node-negative disease supporting their role as a tumor suppressor in breast cancer.
MicroRNAs (miRNAs) are short noncoding RNAs approximately 19-25 nucleotides long that function in the epigenetic control of their target genes. Because the dysregulation of miRNAs is implicated in many different types of cancer, there is an increasing amount of research regarding the role miRNAs specifically in carcinogenesis. 1 The expression of miRNAs is regulated by a variety of mechanisms including environmental factors, DNA methylation, and histone acetylation modifications. 1 Once a particular miRNA is transcribed, it gets processed to become a mature miRNA. The mature miRNA binds to the seed region of its target messenger RNA (mRNA) and either prevents the translation of the mRNA or degrades it. 2 Some miRNAs are described as ''oncogenic,'' because their expression leads to properties promoting cell growth, invasion, and proliferation, whereas others are described as ''tumor suppressive'' as their expression inhibits tumor growth and migration, and promotes apoptosis. Many researchers are interested in the role and expression patterns of miRNAs, because they have the potential to be used as biomarkers to predict prognosis. The problem is that some of the miRNAs demonstrate both oncogenic and tumor-suppressive properties depending upon the context, thus their relevance in the clinical setting is necessary.
MiRNA-18a is thought to be ''tumor-suppressive,'' because Guo et al. found it was underexpressed in human breast cancer. 3 This conflicts with the report that it is overexpressed in estrogen receptor (ER)-negative breast tumors on 171 breast cancer samples, which implicates that it is ''oncogenic.'' 4 In animal models, miRNA-18a high expression leads to decreased spontaneous lung metastasis and tumor growth and increased apoptosis in vitro in response to hypoxic and acidotic conditions, supporting its role as tumor suppressive. 5 In contrast, Mouw et al. found that miRNA-18a high expression leads to the opposite result in response to different environmental conditions, favoring an oncogenic role. 6 MiRNA-205 expression is decreased in breast cancer and increased in normal breast tissue, which implicates that it is a ''tumor-suppressive'' miRNA. In animal models, high expression of miRNA-205 results in a decrease in spontaneous lung metastasis and inhibition of cell proliferation, anchorage independent growth, and cell invasion. MiRNA-205 is implicated in reducing the invasive and migratory potential in both breast and prostate cancer cells by increasing E cadherin, although they use different targets. 8, 9 However, in endometrial cancer cells, miRNA-205 high expression is associated with tumor progression and worse prognosis by suppressing phosphatase and tensin homolog (PTEN). 10 In breast cancer cells, overexpression of miRNA-744 is described as a ''tumor-suppressive'' miRNA in vitro. 11 Similarly, in cervical cancer cells high expression of miRNA-744 decreases the expression of B cell lymphoma 2 (Bcl2) leading to reduced cellular proliferation in vitro and decreased tumor growth in mice. 12 Contrastingly, miRNA-744 is an ''oncogenic'' miRNA in pancreatic cancer. 13 MiRNA-744 high expression is found to target important negative modulators of the Wnt/b-catenin signaling pathway and leads to an increase in the stem celllike phenotype in pancreatic cancer cells. 13 The Cancer Genome Atlas (TCGA) is a large dataset with both epigenomic data and robust clinical data from more than 1,000 breast cancer patient samples. 14 We hypothesize that with the statistical power and survival data of TCGA, we are able to determine whether expression of miRNAs: miRNA-18a, miRNA-205, and miRNA-744 are associated with an improved survival in breast cancer.
MATERIALS/METHODS
Acquiring miRNA-seq and Clinical Data from TCGA Both the clinical data and the miRNA-Seq data were acquired from TCGA breast cancer cohort within the Genomic Data Common (GDC) data portal. In total, 1052 of 1097 breast cancer samples logged in TCGA had both the survival data and miRNA-Seq data available for analysis. An institutional review board was not required because all information within TCGA is publicly accessible and de-identified. 15 Samples were collected from patients with untreated breast cancer. Briefly, each frozen tumor sample was paired with normal breast tissue and processed by the Biospecimen Core Resource. 16 ,17 DNA and RNA extraction was performed using the DNA/RNA All prep kit (Qiagen). The RNA was processed and sent to Genome Characterization Centers (GSCs) and Genome Sequencing Centers (GSCs) where they were sequenced. These results were then sent to the TCGA Research network and further analyzed, interpreted, and made publically available. [16] [17] [18] The breast cancer cohort within TCGA was last updated on May 31, 2016. 24 
Survival Analysis
The clinical information from the breast cancer cohort of patients within TCGA was individually reviewed for overall survival (OS) event times. A total of 1052 of 1097 patient samples, had both survival event data as well as miRNA expression data and were used for our analysis. For the patients without an event (death), their censored survival time was calculated based on the last follow-up date.
Using a gene-specific threshold, the expression of each miRNA was classified as ''high expression'' when the expression levels of the miRNA were above this threshold and ''low expression'' if it did not meet the threshold. The gene-specific thresholds were obtained as described by Ramanathan et al. 15 The Cox proportional hazard model was used to compare the OS in the high-versus lowexpression groups. For the subanalyses, we also looked at estrogen, progesterone, and Her2-neu receptor status (ER, PR, and Her2) and the TNM stages according to the AJCC 7th edition.
RESULTS

Patient Characteristics
The clinical and pathological characteristics were obtained from the breast cohort within TCGA and are listed in Table 1 . The majority of the patients were Caucasian (69.7%) and older than age 50 years (72.9%; Table 1 ). Additionally, 75% of the patients had stage I and II breast cancers, with only 1.9% of the patients presenting with stage IV breast cancer (Fig. 1) . ER was positive in 74%, PR was positive in 64%, and Her2 was positive in 33% of the patients (Table 1) .
Selection of the MicroRNAs
By performing a literature search using Pubmed Central, we chose three microRNAs, miRNA-18a, miRNA-205, and miRNA-744, with conflicting or unknown roles in breast cancer. MiRNA-18a and miRNA-205 have been described as both tumor suppressive and oncogenic in breast cancer, as well as other cancers. MiRNA-744 has been found to be oncogenic in pancreatic cancer and tumor suppressive in breast cancer cells in vitro. We then used the clinical and epigenetic information within a large cohort of breast cancer patients logged in the Cancer Genome Atlas (TCGA) to validate whether high expression of these microRNAs was associated with an improved survival or worse survival.
Survival Advantage of miRNA-18a was Only Statistically Significant in ER-Positive, Lymph Node Metastasis Negative, Distant Metastasis-Free Patients
When evaluating the effect miRNA-18a expression had on survival, a survival advantage was seen in the group that overexpressed miRNA-18a; however, this was not statistically significant (Fig. 2a: n-High = 970, n-low = 82; p = 0.079). Interestingly, in the subanalysis, an association with an improved survival with miRNA-18a was statistically significant when looking at ER-positive cancers (Fig. 2b : n-High = 717, n-low = 62; p = 0.039), as well as PR-positive, or Her2-negative patients (data not shown). For Her2-positive and triple-negative breast cancers (TNBC), there was an association with a worse survival when miRNA-18a was overexpressed; however, this was not statistically significant ( Fig. 2c : n-High = 321, n-low = 24; p = 0.385) (Fig. 2d : n-High = 103, n-low = 7; p = 0.61). When patients did not demonstrate any regional or distant metastases, the high expression of miRNA-18a was also associated with improved survival (Fig. 2e : n-High = 467, n-low = 36; p = 0.053) (Fig. 2g : n-High = 805, n-low = 72; p = 0.023). For patients with one to three positive lymph nodes, the two expression groups seemed to have similar survival patterns ( Fig. 2f : n-High = 318, n-low = 33, p = 0.933), not statistically significant, and intriguingly, all of the patients with distant metastases were within the high-expression group (Fig. 2h: n-High = 20, n-low = 0, p = n/a). High expression of For miRNA-205, its high expression was associated with better survival when all patients were analyzed ( Fig. 3a: n-High = 422, n-low = 630, p = 0.034). Subanalysis revealed that the high expression of miRNA-205 in ER-positive patients was associated with improved survival (Fig. 3b : n-High = 312, n-low = 467, p = 0.036.) In fact, a positive association with survival and miRNA-205 expression also was seen in Her2-positive and TNBC patients (not statistically significant) (Fig. 3c : n-High = 131, n-low = 214, p = 0.015) (Fig. 3d : n-High = 48, n-low = 62, p = 0.286). Similar to miRNA18a, in N0 and M0 disease, a positive association with survival was seen with miRNA-205 high expression, although only significant in N0 disease (Fig. 3e : n-High = 210, n-low = 293, p = 0.017) (Fig. 3g : n-High = 366, n-low = 511, p = 0.077). There was no association with survival in lymph node-positive cancers (Fig. 3f : n-High = 139, n-low = 212, p = 0.65) and appeared to have a worse survival in metastatic cancers, again not statistically significant (Fig. 3h : n-High = 3, n-low = 17, p = 0.237).
High Expression of miRNA-744 Significantly Associated with Prolonged Overall Survival
Last, high expression of miRNA-744 was found to have an improved survival in breast cancer (Fig. 4a : n-High = 318, n-low = 734, p = 0.014). This improved survival was seen in ER-positive patients ( Fig. 4b : n-High = 237, n-low = 542, p = 0.048) but not Her2-positive patients (Fig. 4c : n-High = 118, n-low = 227, p = 0.734). There did appear to be better survival in TNBC when miRNA-744 was expressed high, but our results were not significant (Fig. 4d : n-High = 32, n-low = 78, p = 0.248). Again, we found a survival advantage when miRNA-744 was overexpressed in cancers that were N0 and M0 (Fig. 4e : n-High = 151, n-low = 352, p = 0.0139) (Fig. 4g : n-High = 101, n-low = 250, p = 0.66). In lymph node-positive cancers and e Subanalysis involving lymph node-negative patients: n-High = 467; n-low = 36. f Subanalysis involving patients with 1-3 positive lymph nodes: n-High = 318; n-low = 33. g Subanalysis involving patients without distant metastasis: n-High = 805; n-low = 72. h Subanalysis involving patients with distant metastasis: n-High = 20; n-low = 0 cancers with metastases, there was no clear association with survival when miRNA-744 was expressed high.
DISCUSSION
By using TCGA, we found that high expression of miRNA-18a and miRNA-205 in breast cancer was associated with an improved survival, especially in earlierstage breast cancers, and validated a role for miRNA-744 in breast cancer as tumor suppressive in this cohort of 1052 patients.
Many target genes of miRNA-18a have been described, including hypoxia-inducible factor 1-a (HIF1-a), homeobox protein A9 (HOXA9), and estrogen receptor a (ERa). 5, 6, 19 MiRNA-18a has been found to suppress these targets in response to different environmental stimuli, which may or may not favor cancer. For example, when cells were exposed to hypoxic and acidotic conditions, ectopic miRNA-18a expression was found to decrease the viability of the cells by suppressing the expression of HIF1a. 5 On the other hand, extracellular matrix stiffness was found to induce miRNA-18a expression leading to suppression of HOXA9, which led to the suppression of PTEN and enhanced activity of phosphoinositide 3-kinase (Pi3 K) in vitro leading to a more malignant phenotype in breast cancer cells lines. 6 Additional targets of miRNA-18a include ERa; however, the clinical significance of this interaction in breast cancer is not clear. 4, 5 Guo et al. found that miRNA-18a was underexpressed in ER-negative breast cancer tissues, but Yoshimoto et al. found the opposite result. 19 Although our results showed that high expression of miRNA-18a was associated with an improved survival in ER/PR-positive, Her2-negative, and earlier-stage breast cancers, the exact mechanism for this association is unclear. To clarify the role of miRNA-18a in breast cancer patients, further studies looking at the expression patterns of miRNA-18a and its target genes need to be performed.
MiRNA-18a down-regulation was correlated with an improved survival, implying an oncogenic role.
4,20
Although we do not have any data to explain why our results are different from their observation, one possibility may be a result of different biology of breast cancers that originate from different ethnic backgrounds. e Subanalysis involving lymph node-negative patients: n-High = 210; n-low = 293. f Subanalysis involving patients with 1-3 positive lymph nodes: n-High = 139; n-low = 212. g Subanalysis involving patients without distant metastasis: n-High = 366; n-low = 511. h Subanalysis involving patients with distant metastasis: n-High = 3; n-low = 17 expression group in early-stage cancers is in agreement with the notion that miRNA-205 suppresses tumor progression by preventing EMT in breast cancer. 22 We found that high expression of miR-744 was also associated with improved survival, especially in the earlier stages of breast cancer. This is in agreement with what Vislovukh et al. found in breast cancer cell lines, as the in vitro experiments revealed a decrease in the proliferation of breast cancer cells when miRNA-744 was overexpressed. 11 Similarly, miRNA-744 was expressed low in cervical cancer cells. Animal models of miRNA-744 high expression revealed a decrease in the size of the tumors, and in vitro experiments showed impaired proliferation of cervical cancers. On the other hand, miRNA-744 appeared to demonstrate an oncogenic phenotype in pancreatic cancer, where its high expression was associated with increased recurrences, lymph node metastasis, and poor survival. 13, 23 We do not have a good explanation for this conflicting result other than the fact that miRNA-744 may function differently in different cancers. Further studies are warranted to elucidate the specific roles of miRNA-744 in each cancer and how they develop the differences.
There are several limitations to this study. The survival advantage seen amongst all three miRNAs-18a, 205, and 744 in early-stage ER-positive breast cancers was an unexpected finding and may reflect an unknown biology present within early-stage, ER-positive breast cancers causing overexpression of these miRNAs. Further studies within different breast cancer cohorts are warranted. We have only explored one of the databases collecting both genomic and clinical data to validate the roles of the miRNAs in breast cancer. In addition, when performing our subanalyses, some of the subgroups studied did not have sufficient sample size, and thus our results for these groups may not reach statistical significance simply due to less power, especially for the TNBC cohort and patients with metastatic disease. Despite these limitations, we have found that TCGA, as one validation cohort, may improve our knowledge of how different miRNAs are functioning in different cancers.
CONCLUSIONS
We used TCGA to verify the roles of miRNA-18a, miRNA-205, and miRNA-744 as tumor-suppressive microRNAs in earlier-stage breast cancers as their high expression was associated with improved survival. We chose to look at only three different miRNAs with unclear roles in breast cancer; however, as more information regarding the function of varying miRNAs becomes e Subanalysis involving lymph node-negative patients; n-High = 151; n-low = 352. f Subanalysis involving patients with 1-3 positive lymph nodes; n-High = 101; n-low = 250. g Subanalysis involving patients without distant metastasis; n-High = 270; n-low = 607. h Subanalysis involving patients with distant metastasis; n-High = 5; n-low = 15 available, we can continue to use the data within TCGA to determine the clinical significance of many different miRNAs. Furthermore, as the roles of miRNAs are more clearly defined as tumor-suppressive or oncogenic in breast cancer, we may be able to identify a specific miRNA expression pattern that can be used as a prognostic indicator for survival.
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